Adverse events observed in at least 5% of patients*
| Conventional DMARDs (n = 145) | 8 mg/kg Tocilizumab (n = 157) | |
|---|---|---|
| *Values are the number (%) of patients. | ||
| DMARDs, disease-modifying antirheumatic drugs; Tocilizumab, humanised anti-interleukin-6 receptor antibody. | ||
| Nasopharyngitis | 47 (32.4) | 56 (35.7) |
| Rash | 6 (4.1) | 17 (10.8) |
| Diarrhoea | 13 (9.0) | 13 (8.3) |
| Headache | 3 (2.1) | 11 (7.0) |
| Stomatitis | 13 (9.0) | 9 (5.7) |
| Eczema | 6 (4.1) | 9 (5.7) |
| Nausea | 2 (1.4) | 9 (5.7) |
| Pruritus | 2 (1.4) | 9 (5.7) |
| Paronychia | 1 (0.7) | 9 (5.7) |
| Vomiting | 5 (3.4) | 8 (5.1) |
| Vertebral compression fracture | 8 (5.5) | 3 (1.9) |